ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences hiv-1 replication and disease progression

Clinical Infectious Diseases

Volumn 50, Issue 7, 2010, Pages 1022-1032

  Ballana, Ester ^a   Senserrich, Jordi ^a   Pauls, Eduardo ^a   Faner, Rosa ^b   Mercader, Josep Maria ^c   Uyttebroeck, Frédéric ^d   Palou, Eduard ^b   Mena, Maria Pau ^a   Grau, Eulalia ^a   Clotet, Bonaventura ^a   Ruiz, Lidia ^a   Telenti, Amalio ^d   Ciuffi, Angela ^e   Este, José A ^e  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Laboratori d'Immunobiologia Per a la Recerca I Aplicacions Diagnostiques   (Spain)

^c BARCELONA SUPERCOMPUTING CENTER   (Spain)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOID CELL; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSCRIPTION; ZINC RIBBON DOMAIN CONTAINING 1;

CELL LINE, TUMOR; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENETIC ASSOCIATION STUDIES; GENETIC COMPLEMENTATION TEST; HELA CELLS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMEDIATE-EARLY PROTEINS; LINKAGE DISEQUILIBRIUM; LYMPHOID TISSUE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 77749326542     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651114     Document Type: Article

References (41)

1. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004;36(6):565-574.
2. Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 1998; 67:1-25.
3. 3. Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science 2002; 298(5602):2345-2349. (Pubitemid 36014199)
4. Goff SP. Knockdown screens to knockout HIV-1. Cell 2008; 135(3): 417-420.
5. Goldstein DB. Genomics and biology come together to fight HIV PLoS Biol 2008; 6(3):e76.
6. 6. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319(5865):921-926. (Pubitemid 351263756)
7. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317(5840):944-947.
8. Konig R, Zhou Y, Elleder D, et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008; 135(1):49-60.
9. Zhou H, Xu M, Huang Q, et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008; 4(5): 495-504.
10. Siddiqui RA, Sauermann U, Altmuller J, et al. X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. Am J Hum Genet 2009; 85(2):228-239.
11. Greene WC, Debyser Z, Ikeda Y, et al. Novel targets for HIV therapy. Antiviral Res 2008;80(3):251-265.
12. Lederman MM, Este J. Targeting a host element as a strategy to block HIV replication: is it nice to fool with Mother Nature? Curr Opin HIV AIDS 2009;4(2):79-81.
13. Este JA, Telenti A. HIV entry inhibitors. Lancet 2007; 370(9581):81-88.
14. Hong L, Piao Y, Han Y, et al. Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther 2005; 4(12): 1936-1942.
15. Coriton O, Lepourcelet M, Hampe A, Galibert F, Mosser J. Transcriptional analysis of the 69-kb sequence centromeric to HLA-J: a dense and complex structure of five genes. Mamm Genome 2000; 11(12): 1127-1131.
16. Garcia-Merino I, de Las Cuevas N, Jimenez JL, et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 2009; 6: 27.
17. Scheltinga SA, Johnston-Dow LA, White CB, et al. A generic sequencing based typing approach for the identification of HLA-A diversity. Hum Immunol 1997; 57(2):120-128.
18. 18. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287(5453):646-650. (Pubitemid 30070911)
19. Senserrich J, Pauls E, Armand-Ugon M, et al. HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region. Virology 2008;372(2):421-429.
20. Ballana E, Pauls E, Senserrich J, et al. Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. Blood 2009; 113(6):1278-1286.
21. 21. Armand-Ugon M, Gutierrez A, Clotet B, Este JA. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res 2003; 59: 137-142. (Pubitemid 36929990)
22. 22. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol 2002;76(21):10942-10950. (Pubitemid 35176211)
23. 23. Ciuffi A, Bleiber G, Munoz M, et al. Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol 2004; 78(19):10747-10754. (Pubitemid 39258400)
24. Moncunill G, Armand-Ugon M, Clotet-Codina I, et al. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026. Mol Pharmacol 2008; 73(4):1264-1273.
25. 25. Moncunill G, Armand-Ugon M, Pauls E, Clotet B, Este JA. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 2008;22(1):23-31. (Pubitemid 350294874)
26. 26. Pauls E, Senserrich J, Clotet B, Este JA. Inhibition of HIV-1 replication by RNA interference of p53 expression. J Leukoc Biol 2006; 80(3): 659-667. (Pubitemid 44835799)
27. 27. Gonzalez JR, Armengol L, Sole X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007;23(5):644-645. (Pubitemid 46522604)
28. 28. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7(10):781-791. (Pubitemid 44413222)
29. 29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21(2):263-265. (Pubitemid 40202029)
30. van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, van't Wout AB, Schuitemaker H. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009; 23(1): 19-28.
31. Limou S, Le Clerc S, Coulonges C, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009; 199(3):419-426.
32. Catano G, Kulkami H, He W, et al. HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS One 2008; 3(11): e3636.
33. Dalmasso C, Carpentier W, Meyer L, et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One 2008; 3(12): e3907.
34. Bushman FD, Malani N, Fernandes J, et al. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 2009; 5(5):e1000437.
35. Goff SP. Host factors exploited by retroviruses. Nat. Rev. Microbiol. 2007; 5(4):253-263.
36. Telenti A, Goldstein DB. Genomics meets HIV-1. Nat. Rev. Microbiol. 2006; 4(11):865-873.
37. Trachtenberg E, Bhattacharya T, Ladner M, Phair J, Erlich H, Wolinsky S. The HLA-B/-C haplotype block contains major determinants for host control of HIV Genes Immun 2009; 10(8):673-677.
38. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136(4):642-655.
39. Stranger BE, Nica AC, Forrest MS, et al. Population genomics of human gene expression. Nat Genet 2007; 39(10):1217-1224.
40. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49(11):4721-4732.
41. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359(14): 1429-1441.